FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2234202104> ?p ?o ?g. }

• W2234202104 endingPage "334" @default.
• W2234202104 startingPage "328" @default.
• W2234202104 abstract "•Validation of 3 T MRI DWI for lymph node staging of mainly high risk prostate cancer. •Patients correctly diagnosed with metastasis had many and large involved nodes. •Imaging detected 55% of patients with lymph node metastases. •Among patients without lymph node metastases, 10% were misinterpreted as positive. Aim To prospectively validate 3 T magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) for preoperative lymph node (LN) staging in a clinical setting, in intermediate- and high-risk prostate cancer (PCa) patients using laparoscopic extended LN dissection (ePLND) as the reference standard. Materials and methods Between August 2011 and May 2013, 40 newly diagnosed intermediate and high-risk PCa patients underwent preoperative LN staging with 3 T MRI DWI using histopathology of ePLND as the reference standard. The sensitivity, specificity, and accuracy of MRI DWI were calculated. A subgroup analysis of proven LN-positive patients was made to investigate differences in PSA, Gleason score, number, and size of LN metastases, estimated risk of LN involvement, and if curative treatment was indicated, between the true-positive and the false-negative groups. Results A total of 728 LN were harvested from six anatomical regions per patient (external, obturator, internal) with a mean number of 18 LNs per patient (range 11–40). Twenty patients had histologically proven LN-positive disease. MRI DWI was true positive in 11 patients, false negative in nine patients, false positive in two patients, and true negative in 18 patients, resulting in 90% specificity, 55% sensitivity, and 72.5% accuracy. The true-positive patients had significantly more involved LNs (mean 6.9 versus 2.7, p=0.017), with larger diameter (mean 12.3 versus 5.2 mm, p=0.048) and fewer were treated with curative intent (six versus nine, p=0.03), compared with the false-negative group. Conclusion MRI DWI LN staging has a low sensitivity but high specificity. The true-positive patients have a considerably higher burden of LN metastases compared to false-negative patients. To prospectively validate 3 T magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) for preoperative lymph node (LN) staging in a clinical setting, in intermediate- and high-risk prostate cancer (PCa) patients using laparoscopic extended LN dissection (ePLND) as the reference standard. Between August 2011 and May 2013, 40 newly diagnosed intermediate and high-risk PCa patients underwent preoperative LN staging with 3 T MRI DWI using histopathology of ePLND as the reference standard. The sensitivity, specificity, and accuracy of MRI DWI were calculated. A subgroup analysis of proven LN-positive patients was made to investigate differences in PSA, Gleason score, number, and size of LN metastases, estimated risk of LN involvement, and if curative treatment was indicated, between the true-positive and the false-negative groups. A total of 728 LN were harvested from six anatomical regions per patient (external, obturator, internal) with a mean number of 18 LNs per patient (range 11–40). Twenty patients had histologically proven LN-positive disease. MRI DWI was true positive in 11 patients, false negative in nine patients, false positive in two patients, and true negative in 18 patients, resulting in 90% specificity, 55% sensitivity, and 72.5% accuracy. The true-positive patients had significantly more involved LNs (mean 6.9 versus 2.7, p=0.017), with larger diameter (mean 12.3 versus 5.2 mm, p=0.048) and fewer were treated with curative intent (six versus nine, p=0.03), compared with the false-negative group. MRI DWI LN staging has a low sensitivity but high specificity. The true-positive patients have a considerably higher burden of LN metastases compared to false-negative patients." @default.
• W2234202104 created "2016-06-24" @default.
• W2234202104 creator A5011722950 @default.
• W2234202104 creator A5013734979 @default.
• W2234202104 creator A5021479531 @default.
• W2234202104 creator A5023269056 @default.
• W2234202104 creator A5053328244 @default.
• W2234202104 creator A5068318304 @default.
• W2234202104 creator A5074744300 @default.
• W2234202104 creator A5076487067 @default.
• W2234202104 date "2016-04-01" @default.
• W2234202104 modified "2023-10-15" @default.
• W2234202104 title "Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer" @default.
• W2234202104 cites W1819910556 @default.
• W2234202104 cites W1965617754 @default.
• W2234202104 cites W1974264125 @default.
• W2234202104 cites W1976625532 @default.
• W2234202104 cites W1979053998 @default.
• W2234202104 cites W1981989535 @default.
• W2234202104 cites W1996080642 @default.
• W2234202104 cites W1998156409 @default.
• W2234202104 cites W2005541255 @default.
• W2234202104 cites W2015831404 @default.
• W2234202104 cites W2027236201 @default.
• W2234202104 cites W2031729386 @default.
• W2234202104 cites W2037073425 @default.
• W2234202104 cites W2041873623 @default.
• W2234202104 cites W2048266675 @default.
• W2234202104 cites W2065617498 @default.
• W2234202104 cites W2066758446 @default.
• W2234202104 cites W2080006760 @default.
• W2234202104 cites W2088837012 @default.
• W2234202104 cites W2106129787 @default.
• W2234202104 cites W2112887165 @default.
• W2234202104 cites W2116692433 @default.
• W2234202104 cites W2116810900 @default.
• W2234202104 cites W2117441254 @default.
• W2234202104 cites W2121257596 @default.
• W2234202104 cites W2124539070 @default.
• W2234202104 cites W2124586180 @default.
• W2234202104 cites W2142262182 @default.
• W2234202104 cites W2143802196 @default.
• W2234202104 cites W2144668692 @default.
• W2234202104 cites W2146141124 @default.
• W2234202104 cites W2147689915 @default.
• W2234202104 cites W2148677781 @default.
• W2234202104 cites W2154847774 @default.
• W2234202104 cites W2172152967 @default.
• W2234202104 cites W3023689102 @default.
• W2234202104 cites W4321059169 @default.
• W2234202104 cites W4322701587 @default.
• W2234202104 doi "https://doi.org/10.1016/j.crad.2015.12.001" @default.
• W2234202104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26774372" @default.
• W2234202104 hasPublicationYear "2016" @default.
• W2234202104 type Work @default.
• W2234202104 sameAs 2234202104 @default.
• W2234202104 citedByCount "32" @default.
• W2234202104 countsByYear W22342021042016 @default.
• W2234202104 countsByYear W22342021042017 @default.
• W2234202104 countsByYear W22342021042018 @default.
• W2234202104 countsByYear W22342021042019 @default.
• W2234202104 countsByYear W22342021042020 @default.
• W2234202104 countsByYear W22342021042021 @default.
• W2234202104 countsByYear W22342021042022 @default.
• W2234202104 countsByYear W22342021042023 @default.
• W2234202104 crossrefType "journal-article" @default.
• W2234202104 hasAuthorship W2234202104A5011722950 @default.
• W2234202104 hasAuthorship W2234202104A5013734979 @default.
• W2234202104 hasAuthorship W2234202104A5021479531 @default.
• W2234202104 hasAuthorship W2234202104A5023269056 @default.
• W2234202104 hasAuthorship W2234202104A5053328244 @default.
• W2234202104 hasAuthorship W2234202104A5068318304 @default.
• W2234202104 hasAuthorship W2234202104A5074744300 @default.
• W2234202104 hasAuthorship W2234202104A5076487067 @default.
• W2234202104 hasConcept C121608353 @default.
• W2234202104 hasConcept C126322002 @default.
• W2234202104 hasConcept C126838900 @default.
• W2234202104 hasConcept C142724271 @default.
• W2234202104 hasConcept C143409427 @default.
• W2234202104 hasConcept C149550507 @default.
• W2234202104 hasConcept C2775862295 @default.
• W2234202104 hasConcept C2779013556 @default.
• W2234202104 hasConcept C2779720271 @default.
• W2234202104 hasConcept C2780192828 @default.
• W2234202104 hasConcept C2780849966 @default.
• W2234202104 hasConcept C2989005 @default.
• W2234202104 hasConcept C544855455 @default.
• W2234202104 hasConcept C71924100 @default.
• W2234202104 hasConceptScore W2234202104C121608353 @default.
• W2234202104 hasConceptScore W2234202104C126322002 @default.
• W2234202104 hasConceptScore W2234202104C126838900 @default.
• W2234202104 hasConceptScore W2234202104C142724271 @default.
• W2234202104 hasConceptScore W2234202104C143409427 @default.
• W2234202104 hasConceptScore W2234202104C149550507 @default.
• W2234202104 hasConceptScore W2234202104C2775862295 @default.
• W2234202104 hasConceptScore W2234202104C2779013556 @default.
• W2234202104 hasConceptScore W2234202104C2779720271 @default.
• W2234202104 hasConceptScore W2234202104C2780192828 @default.

• next